Accretropin approved for pediatric growth failure

Cangene has received FDA approval for Accretropin (recombinant somatropin injection), a human growth hormone (rhGH) for the treatment of children with growth failure due to an inadequate secretion of endogenous growth hormone and for the treatment of short stature associated with Turner Syndrome, an X-chromosome linked genetic disorder.

For more information call (204) 275-4178 or visit www.cangene.com.